TSO3 — Investor Presentation (2012)
45 slides from TSO3's investor presentation, Oct 30, 2012
Slide 1: Corporate presentation Updated Q2 2012
Corporate presentation Updated Q2 2012 Creating the Improved Standard in Healthcare Sterile Reprocessing
Slide 2: Company Overview
Company Overview • Founded 1998 • Designed and manufactured a low temperature sterilizer for medical devices • IPO 2001 • TSX: TOS • 59M shares outstanding
Slide 3: Key Events Under Initial Management
Key Events Under Initial Management 2002 • Received HC Authorization for first generation sterilizer (125L) 2003 • Received FDA Clearance for first generation sterilizer (125L) 2006 • Received FDA Clearance for additional claims to include rigid lumened instruments (125L) 2008 • TSO3 total 38 placem
Slide 4: Historical Key Events
Historical Key Events 1998 - 2008 • Initial sterilization platform (limitations in offering as per cycle times and compatibility) Regulatory clearance in Canada and the United States Sold directly by TSO3 with limited success (38 units /5 years) 2009-2010 • Renewed direction • Second generation
Slide 5: Organizational Structure
Organizational Structure R.M. (Ric) Rumble, CEO – Joined October 2008 • More than 25 years experience within the North American and Global medical device industry, capital and consumables • Business Unit Manager, Sterility Assurance – 3M • President/CEO - MediVators Inc • VP & GM – Global Healthcare
Slide 6: Our Vision
Our Vision… To Create the Improved Standard in Healthcare Sterile Reprocessing
Slide 7: Opportunity
Opportunity Medical Sterile Reprocessing of Reusable Instruments 7
Slide 8: In business to win
In business to win The Product/ Solution The Market The Channel
Slide 9: Why low temperature sterilization?
Why low temperature sterilization?
Slide 10: Market Drivers
Market Drivers 10
Slide 11: Growing Population
Growing Population 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 12: Aging Population
Aging Population 60 53% 50 increase 65 yrs + 40 45 to 64 % Increase 15 to 44 30 - 15 yrs 20 10 0 2001 2005 2010 2015 2020 65 yrs+ is the fastest growing segment Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 13: Impact of Age on Demand for Surgery
Impact of Age on Demand for Surgery 88% of ophthalmology surgeries Number of 70% of cardiothoracic surgeries procedures (average) 65% of urology surgeries 60% of general surgeries Age 45 55 65 75 As we age, we require more OR time Annals of Surgery. 2003 August; 238(2): 170-177.
Slide 14: Advancement in Medical Techniques
Advancement in Medical Techniques From Traditional Open Surgery To Minimally Invasive Surgery (MIS) 14
Slide 15: MIS Procedures
MIS Procedures Increasingly used and finding new applications everyday Orthopaedic Neurosurgery Pulmonary medicine 30 million MIS Gynaecology surgeries in US/year Urology Gastrointestinal Cardiology 15 The National Institute of Health (NIH).
Slide 16: MIS Devices are Complex & Delicate
MIS Devices are Complex & Delicate $50k Colonoscope 16
Slide 17: MIS Devices require low temperature sterilization
MIS Devices require low temperature sterilization
Slide 18: Sterilization Areas in Hospitals
Sterilization Areas in Hospitals 2 OR 1 CS OR OR OR OR Central Sterilization (CS) Operating Room Department (OR) Low Temperature Sterilization OR OR OR OR Gas Liquid OR Reprocessing and Sterile Storage Steam Sterilization 3 GI Gastrointestinal Department (GI) Liquid 18
Slide 19: Customers want Throughput
Customers want THROUGHPUT TSO3 sterilizer conjoint study July 2009 - Allegheny Marketing Group.
Slide 20: Available Sterilization Solutions
Available Sterilization Solutions Ethylene Oxyde Hydrogen Peroxide Liquid Hyg. Per. + Ozone (EtO) (H2O2) Peracetic Acid (PAA) (H2O2/O3) Efficacious Fast Specific use in OR Fast High material Limited in Liquid = Not terminal Efficacious compatibility efficacy sterilization Long cycles Limited in Repl
Slide 21: Our Technology Enables Throughput
Our Technology Enables Throughput By combining: • Efficacy & Compatibility • High loading capacity • Speed 21
Slide 22: Customer Feedback
Customer Feedback • “Improving our standard of care by terminally sterilizing devices previously reprocessed using a liquid chemical sterilization method” • “Virtually eliminated the use of the liquid process, as flexible scopes are now terminally sterilized, along with additional devices” • “Runnin
Slide 23: Market Overview / Low Temperature Sterilization
Market Overview / Low Temperature Sterilization • Capital equipment business Worldwide Installed Base – Low temperature gas sterilizers in hospitals: • ~26,000 installed worldwide • Life span ~ 12 years US • Replacement business: 2,000 units/year Canada Europe • Consummables business ROW – Estimated
Slide 24: Channel Partnership
Channel Partnership • Signed agreement with 3M in December 2009 for the exclusive supply, distribution, license and service of the new STERIZONE® 125L+ Sterilizer; • Amended agreement in May 2011 to include new sterilizer intended for the OR Sub-Sterile Area in hospitals (STERIZONE® 80L+ Sterilizer)
Slide 25: Preferred Partnership
Preferred Partnership • Global in scope • Reputation and credibility at end-user level • Experience in capital sales • Direct experience in after sales service • Mutually beneficial – Market reach for TSO3 – Bolt-on product/technology to existing offering for channel partner 25
Slide 26: Recent Announcement
Recent Announcement Home | Services | Beyond the Wire | About CNW Register / Login | Francais CNW pews meets oni CANADA NEWSWIRE S&P/TSX Comp 11835.10 ¥ -23.03(-0.19) S&PITSXV Comp 1190.54 ¥ -2.51(-0.21) DJIA 13165.19 ¥ -10.45 (-0.08) MORE FINANCIALS ¥ August 7, 2012 1:50 PM - Financial - Business a
Slide 27: Getinge Group
Getinge Group • World’s leading provider of disinfectors and sterilizers within the healthcare and life sciences segments • Represents innovation and technological progress in the fields of disinfection and sterilization • 31 subsidiaries on six continents and over 230 distributors and partner compa
Slide 28: Getinge Infection Prevention
Getinge Infection Prevention - Revenue: $780M - Associates: 3 104 - Sales companies: 36 - Plants: 9 28
Slide 29: Activities and Results
Activities and Results 29
Slide 30: Key Strategic Activities
Key Strategic Activities • Regulatory • Commercial • Enhanced Portfolio 30
Slide 31: Regulatory Status USA
Regulatory Status USA • Changing regulatory environment / request to re-file through new process • Re-filed June 30, 2011 • Subsequent additional data requested by Agency - filed April 20, 2012 Active file in progress - 11 months through the process 31
Slide 32: What is moving through the US Regulatory Process from TSO3?
What is moving through the US Regulatory Process from TSO3? Biological Indicator (BI) Process Indicator (CI) Test Pack Sterile Efficacy Validation Sterilizer 32
Slide 33: Market Potential
Market Potential 33
Slide 34: Revenues on Unit Sale over 10-year
Revenues on Unit Sale over 10-year End-User Price $ 640k $480k $320k Margins $160k 1 2 3 4 5 6 7 8 9 10 Year 34
Slide 35: Next Product
Next Product • STERIZONE® 80L Sterilizer • Market : OR Sub-Sterile Area • Inventory limitations, flexibility in schedule, shorter turn-around time • Potential placements (NA): > 7,500 units • 50% of customers surveyed want the product Features • Multiple devices in same load • Mix of lumened and sur
Slide 36: STERIZONE 80L Sterilizer
STERIZONE® 80L Sterilizer 36
Slide 37: STERIZONE 80L Sterilizer
STERIZONE® 80L Sterilizer • Market : OR Sub-Sterile Area • Inventory limitations, flexibility in schedule, shorter turn-around time • Potential placements (NA): > 7,500 units • 50% of customers surveyed want the capability 37
Slide 38: Looking Towards the Future
Looking Towards the Future 38
Slide 39: Our Strengths
Our Strengths • Rapid research & prototyping – Small and flexible structure – Tunable technology • Sterilization testing expertise – Microbiology – Materials compatibility testing • Positive regulatory track record • Licensing-out 39
Slide 40: Growth Strategy
Growth Strategy • Obtain Regulatory Clearance • Secure channel partner and support • Increase portfolio – New developments – Acquisitions /Joint ventures • Maintain focus in current space – Medical sterile reprocessing 40
Slide 41: Creating Value
Creating Value • Our offering – Technology and competency based • Our targets – Medical device manufacturers – Sales channels – Investors • Our tactics – Web based – OEM channel 41
Slide 42: What to expect in the next 12 months?
What to expect in the next 12 months ? • Obtain United States regulatory clearance of the STERIZONE® 125L+ Sterilizer; • Secure the desired channel partner agreement; • Support the channel partner in launching the STERIZONE® 125L+ Sterilizer in territories where marketing clearance has been obtained
Slide 43: Financial Situation – As of June 30
Financial Situation – As of June 30 June 2012 (000’s) Total Revenue – last 12 months* 3,606 Cash, Cash Equivalents & Temporary Investments 16,499 Inventories 1,011 Total Assets 22,729 Equity 21,526 Monthly Burn Rate 750** Shares Outstanding 65,888 Options and Warrants Outstanding 7,510 * Excluding t
Slide 44: Investment Highlights
Investment Highlights Large and growing market Superior technology meets customer needs In discussion with strong global channel partner Pursuing new applications and opportunities Financially sound 44
Slide 45: © TSO3 Inc., 2012. All rights reserved.
© TSO3 Inc., 2012. All rights reserved. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc. - OZO-TEST® - STERIZONE® are Reg. U.S. Pat. & Tm. Off. TSO3 STERIZONE® Sterilizer U.S. Pat. No. 7,128,872 / 7,582,257 / 7